Home › Compare › ASHXF vs ABBV
ASHXF yields 888.89% · ABBV yields 3.06%● Live data
📍 ASHXF pulled ahead of the other in Year 1
Combined, ASHXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ASHXF + ABBV for your $10,000?
Progressive Planet Solutions Inc., together with its subsidiaries, engages in the acquisition and exploration of mineral properties in Canada. It primarily explores for natural pozzolan deposits. The company holds 100% interest in the Z1 Zeolite mine located 3 kms northeast of Cache Creek, British Columbia; and the Z3 Heffley property situated in Heffley Creek, British Columbia. It also holds interests in Z2 Zeolite property located near Falkland, British Columbia. In addition, the company is involved in converting post-consumer glass into a low carbon cement; manufacture of mineral based products derived from diatomaceous earth, zeolite, and bentonite for use in agricultural, industrial, and consumer applications; and developing solutions for sequestering CO2 and minimizing the carbon footprint. Further, it manufactures industrial minerals, which include industrial absorbents under the CanDry brand; cat litters under the WunderCat brand for retailers; and animal husbandry/agtech products that neutralizes ammonia in chicken barns and enables the birds to breathe easier under the Activated Barn Fresh brand. Progressive Planet Solutions Inc. was incorporated in 2006 and is headquartered in Kamloops, Canada.
Full ASHXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.